Bob Hugin of Celgene tops a highly qualified field of nominees to win this year's Best Biotech CEO award.
12/11/13 - 10:01 AM EST
Gilead's decision to price Sovaldi at $84,000 per treatment may open door for competitors like Abbvie to gain market share from cost-conscious pharmacy benefits managers.
12/10/13 - 01:56 PM EST
Dont expect stem cell stocks to lag the rest of the biotech sector again in 2014, says Dr. Robin Smith, CEO of Neostem.
12/09/13 - 02:51 PM EST
The new hepatitis C pill is expected to shatter drug launch records with $2 billion in sales in its first year.
12/09/13 - 06:31 AM EST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
12/06/13 - 06:00 AM EST
A big-money partnership with Celgene (CELG) sent OncoMed (OMED) shares sky-high in morning trading.
12/03/13 - 09:46 AM EST
- Tickers in this article:
Leukemia and Lymphoma Society has asked Stemline to stop using cancer patient testimonials in its investor presentations.
12/03/13 - 07:59 AM EST
The cash will paid to top execs if Amarin can win an expansion of its fish-oil pill.
12/03/13 - 07:45 AM EST
All things weren't equal for biopharmaceutical stocks on Monday, with Merrimack (MACK) leaping higher and Orexigen (OREX) plunging lower.
12/02/13 - 11:54 AM EST
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
12/02/13 - 07:00 AM EST
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.
11/27/13 - 07:00 AM EST
After a red-hot start, biotech IPOs are now underperforming the broader market.
11/26/13 - 09:42 AM EST